Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  vorinostat
Find trials that include:  Any drugs shown
Results 1-25 of 27 for your search:
Start Over
Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 0761-010, NCI-2012-02782, NCT01728805
Vorinostat and Combination Chemotherapy with Rituximab in Treating Patients with HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AMC-075, NCI-2011-02508, AMC #75, CDR0000683379, NCT01193842
Vorinostat and Etoposide in Treating Younger Patients With Refractory or Relapsed Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 4 to 21
Trial IDs: 10-096, NCI-2011-00493, NCT01294670
Sorafenib, Vorinostat, and Bortezomib in Treating Patients With Acute Myeloid Leukemia
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: IUCRO-0327, NCI-2012-00200, NCT01534260
Vorinostat, Gemcitabine Hydrochloride, and Docetaxel in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-104, NCI-2013-01735, UPCI 12-104, NCT01879085
Pembrolizumab and Vorinostat in Treating Patients with Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9383, NCI-2015-01310, MK-3475, NCT02538510
Lenalidomide and High-Dose Chemotherapy before Stem Cell Transplant in Treating Patients with Relapsed or Refractory, Diffuse Large B-Cell Lymphoma of the ABC Subtype
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 15 to 65
Trial IDs: 2015-0558, NCI-2015-01938, NCT02589145
Temozolomide and Vorinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: HEMAML0017, NCI-2012-00229, 22794, NCT01550224
Vorinostat in Treating Patients with Metastatic Melanoma of the Eye
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AAAO5917, NCI-2012-00860, CUMC-IRBAAAO5917, MSKCC-12-027, 9111, 12-027, NCT01587352
131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinistat
Phase: Phase II
Type: Treatment
Age: Over 24 months to less than 30 years
Trial IDs: N2011-01, NCI-2015-00640, NCT02035137
MRSI in Predicting Early Response in Patients Treated with Radiation Therapy and Temozolomide with or without Belinostat for Newly-Diagnosed Glioblastoma or Gliosarcoma
Phase: Phase II
Type: Diagnostic, Treatment
Age: 18 and over
Trial IDs: WINSHIP2434-13, NCI-2014-01432, NCT02137759
Vorinostat and Hydroxychloroquine or Regorafenib in Treating Patients with Refractory Metastatic Colorectal Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CTMS 14-2015, NCI-2015-00203, 14-2015, 2015, HSC20150178H, NCI-2015-00175, NCT02316340
Pembrolizumab, Tamoxifen Citrate, and Vorinostat in Treating Patients with Hormone Receptor Positive Stage IV Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CC #147523, NCI-2015-00815, 132069, 14-15383, 147523, NCT02395627
Bortezomib, Vorinostat, and Combination Chemotherapy in Treating Infants with Newly Diagnosed Acute Lymphoblastic Leukemia
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 and under
Trial IDs: TINI, NCI-2015-01493, NCT02553460
Vorinostat, Niacinamide, and Etoposide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NYU 09-0621, NCI-2011-02695, NCT00691210
Vorinostat and Iobenguane I 131 in Treating Patients With Resistant or Relapsed Neuroblastoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 2 to 30
Trial IDs: NANT 2007-03, NCI-2009-01450, NANT-N2007-03, N2007-03, NCT01019850
Vorinostat and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CTRC 08-52, NCI-2012-01694, HSC20080462H, NCT01023737
Sorafenib Tosylate and Vorinostat in Treating Patients with Advanced Liver Cancer
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: MCC-12122, NCI-2010-00185, NCT01075113
Sirolimus, Everolimus, or Temsirolimus and Vorinostat in Treating Patients with Advanced Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: 2009-0729, NCI-2011-00562, NCT01087554
Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AMC-078, NCI-2011-02511, CDR0000689900, NCT01249443
Sirolimus or Vorinostat in Combination with Hydroxychloroquine in Treating Patients with Advanced or Metastatic Cancer
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2010-0588, NCI-2011-00303, NCT01266057
Ixazomib Citrate and Vorinostat in Treating Patients with Advanced Solid Tumors or Lymphoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2013-0511, NCI-2014-01091, NCT02042989
Fludarabine Phosphate, Clofarabine, and Busulfan with Vorinostat in Treating Patients with Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 60 and under
Trial IDs: 2012-0999, NCI-2014-01982, NCT02083250
Gemcitabine Hydrochloride, Nab-Paclitaxel, Radiation Therapy, Sorafenib Tosylate, and Vorinostat in Treating Patients with Previously Untreated Pancreatic Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MCC-12-07328, NCI-2015-00017, NCT02349867
Start Over